{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T17:20:24Z","timestamp":1789320024464,"version":"build-2803163510"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R61AG066543"],"award-info":[{"award-number":["R61AG066543"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40263-020-00740-6","type":"journal-article","created":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T09:03:16Z","timestamp":1591434196000},"page":"785-794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Alzheimer\u2019s Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-2094","authenticated-orcid":false,"given":"Michael S.","family":"Rafii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,6]]},"reference":[{"key":"740_CR1","first-page":"259","volume":"3","author":"JLH Down","year":"1866","unstructured":"Down JLH. Observations on an ethnic classification of idiots. Lond Hosp Clin Lect Rep. 1866;3:259\u201362.","journal-title":"Lond Hosp Clin Lect Rep."},{"key":"740_CR2","first-page":"1026","volume":"240","author":"J Lejeune","year":"1959","unstructured":"Lejeune J, Gautier M, Turpin R. A study of somatic chromosomes in nine infants with mongolism. CR Acad Sci (Paris). 1959;240:1026\u20137.","journal-title":"CR Acad Sci (Paris)"},{"key":"740_CR3","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1126\/science.2949367","volume":"235","author":"RE Tanzi","year":"1987","unstructured":"Tanzi RE, Gusella JF, Watkins PC, et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science. 1987;235:880\u20134.","journal-title":"Science"},{"key":"740_CR4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.1925564","volume":"254","author":"J Murrell","year":"1991","unstructured":"Murrell J, Farlow M, Ghetti B, et al. A mutation in the amyloid precursor protein associated with hereditary Alzheimer\u2019s disease. Science. 1991;254:97\u20139.","journal-title":"Science"},{"key":"740_CR5","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/349704a0","volume":"349","author":"A Goate","year":"1991","unstructured":"Goate A, Chartier-Hardin M-C, Mullan M. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature. 1991;349:704\u201376.","journal-title":"Nature"},{"issue":"9311","key":"740_CR6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0140-6736(02)08092-3","volume":"359","author":"Q Yang","year":"2002","unstructured":"Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down\u2019s syndrome in the USA from 1983 to 1997: a population-based study. Lancet. 2002;359(9311):1019\u201325.","journal-title":"Lancet"},{"issue":"2","key":"740_CR7","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/jamaneurol.2019.3666","volume":"77","author":"E Rubenstein","year":"2020","unstructured":"Rubenstein E, Hartley S, Bishop L. Epidemiology of Dementia and Alzheimer Disease in Individuals with Down Syndrome. JAMA Neurol. 2020;77(2):262\u20134.","journal-title":"JAMA Neurol."},{"key":"740_CR8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/jir.12390","volume":"61","author":"M McCarron","year":"2017","unstructured":"McCarron M, McCallion P, Reilly E, et al. A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. J Intellect Disabil Res. 2017;61:843\u201352.","journal-title":"J Intellect Disabil Res"},{"issue":"2","key":"740_CR9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2018.3616","volume":"76","author":"R Hithersay","year":"2019","unstructured":"Hithersay R, Startin CM, Hamburg S, et al. Association of dementia with mortality among adults with down syndrome older than 35 years. JAMA Neurol. 2019;76(2):152\u201360.","journal-title":"JAMA Neurol."},{"issue":"11","key":"740_CR10","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/jamaneurol.2018.2210","volume":"75","author":"E Bayen","year":"2018","unstructured":"Bayen E, Possin KL, Chen Y, et al. Prevalence of aging, dementia, and multimorbidity in older adults with down syndrome. JAMA Neurol. 2018;75(11):1399\u2013406.","journal-title":"JAMA Neurol."},{"issue":"2","key":"740_CR11","doi-asserted-by":"crossref","first-page":"e026614","DOI":"10.1136\/bmjopen-2018-026614","volume":"9","author":"SD Landes","year":"2019","unstructured":"Landes SD, Stevens JD, Turk MA. Obscuring effect of coding developmental disability as the underlying cause of death on mortality trends for adults with developmental disability: a cross-sectional study using US Mortality Data from 2012 to 2016. BMJ Open. 2019;9(2):e026614.","journal-title":"BMJ Open"},{"key":"740_CR12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0168-9525(93)90210-9","volume":"9","author":"SE Antonarakis","year":"1993","unstructured":"Antonarakis SE. Human chromosome 21: genome mapping and exploration circa 1993. Trends Genet. 1993;9:142\u20138.","journal-title":"Trends Genet"},{"key":"740_CR13","first-page":"133","volume-title":"Down syndrome. Advances in biomedicine and the behavioral sciences","author":"HC Thuline","year":"1982","unstructured":"Thuline HC, Pueschel SM. Cytogenetics in Down syndrome. In: Pueschel SM, Rynders JE, editors. Down syndrome. Advances in biomedicine and the behavioral sciences. Cambridge: Ware Press; 1982. p. 133."},{"issue":"1","key":"740_CR14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12929-015-0138-y","volume":"22","author":"A Asim","year":"2015","unstructured":"Asim A, Kumar A, Muthuswamy S, et al. Down syndrome: an insight of the disease. J Biomed Sci. 2015;22(1):41.","journal-title":"J Biomed Sci."},{"key":"740_CR15","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1093\/brain\/awl203","volume":"129","author":"K Sleegers","year":"2006","unstructured":"Sleegers K, Brouwers N, Gijselinck I, et al. APP duplication is sufficient to cause early onset Alzheimer\u2019s dementia with cerebral amyloid angiopathy. Brain. 2006;129:2977\u201383.","journal-title":"Brain"},{"key":"740_CR16","doi-asserted-by":"crossref","first-page":"426.e13","DOI":"10.1016\/j.neurobiolaging.2010.10.010","volume":"33","author":"D McNaughton","year":"2012","unstructured":"McNaughton D, Knight W, Guerreiro R, et al. Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. Neurobiol Aging. 2012;33:426.e13\u201321.","journal-title":"Neurobiol Aging"},{"key":"740_CR17","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1056\/NEJM198906013202203","volume":"320","author":"B Rumble","year":"1989","unstructured":"Rumble B, Retallack R, Hilbich C, et al. Amyloid A4 and its precursor in Down\u2019s syndrome and Alzheimer\u2019s disease. N Engl J Med. 1989;320:1446\u201362.","journal-title":"N Engl J Med"},{"key":"740_CR18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ng1718","volume":"38","author":"A Rovelet-Lecrux","year":"2006","unstructured":"Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38:24\u20136.","journal-title":"Nat Genet"},{"key":"740_CR19","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1093\/brain\/awl237","volume":"129","author":"L Cabrejo","year":"2006","unstructured":"Cabrejo L, Guyant-Mar\u00e9chal L, Laquerri\u00e8re A, et al. Phenotype associated with APP duplication in five families. Brain. 2006;129:2966\u201376.","journal-title":"Brain"},{"key":"740_CR20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3233\/JAD-2012-120172","volume":"30","author":"D Wallon","year":"2012","unstructured":"Wallon D, Rousseau S, Rovelet-Lecrux A, et al. The French series of autosomal dominant early onset Alzheimer\u2019s disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J Alzheimers Dis. 2012;30:847\u201356.","journal-title":"J Alzheimers Dis."},{"key":"740_CR21","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jalz.2017.03.007","volume":"13","author":"M Carmona-Iragui","year":"2017","unstructured":"Carmona-Iragui M, Balasa M, Benejam B, et al. Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer\u2019s disease. Alzheimers Dement. 2017;13:1251\u201360.","journal-title":"Alzheimers Dement."},{"issue":"1","key":"740_CR22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40478-017-0499-4","volume":"5","author":"E Head","year":"2017","unstructured":"Head E, Phelan MJ, Doran E, et al. Cerebrovascular pathology in Down syndrome and Alzheimer disease. Acta Neuropathol Commun. 2017;5(1):93.","journal-title":"Acta Neuropathol Commun."},{"key":"740_CR23","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ana.410430316","volume":"43","author":"VP Prasher","year":"1998","unstructured":"Prasher VP, Farrer MJ, Kessling AM, et al. Molecular mapping of Alzheimer-type dementia in Down\u2019s syndrome. Ann Neurol. 1998;43:380\u20133.","journal-title":"Ann Neurol"},{"issue":"2","key":"740_CR24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3233\/JAD-160836","volume":"56","author":"E Doran","year":"2017","unstructured":"Doran E, Keator D, Head E, et al. Down syndrome, partial trisomy 21, and absence of Alzheimer\u2019s disease: the role of APP. J Alzheimers Dis. 2017;56(2):459\u201370.","journal-title":"J Alzheimers Dis."},{"issue":"7409","key":"740_CR25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","volume":"488","author":"T Jonsson","year":"2012","unstructured":"Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline. Nature. 2012;488(7409):96\u20139.","journal-title":"Nature"},{"issue":"338","key":"740_CR26","doi-asserted-by":"crossref","first-page":"338ra66","DOI":"10.1126\/scitranslmed.aaf2362","volume":"8","author":"MR Brier","year":"2016","unstructured":"Brier MR, Gordon B, Friedrichsen K, et al. Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease. Sci Transl Med. 2016;8(338):338ra66.","journal-title":"Sci Transl Med"},{"issue":"Pt 5","key":"740_CR27","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139(Pt 5):1551\u201367.","journal-title":"Brain"},{"issue":"Pt. 6","key":"740_CR28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2788.2006.00902.x","volume":"51","author":"ML Margallo-Lana","year":"2007","unstructured":"Margallo-Lana ML, Moore PB, Kay DW, et al. Fifteen-year follow-up of 92 hospitalized adults with Down\u2019s syndrome: incidence of cognitive decline, its relationship to age and neuropathology. J Intellect Disabil Res. 2007;51(Pt. 6):463\u201377.","journal-title":"J Intellect Disabil Res"},{"key":"740_CR29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1750-3639.1991.tb00667.x","volume":"1","author":"K Beyreuther","year":"1991","unstructured":"Beyreuther K, Masters CL. Amyloid precursor protein (APP) and beta A4 amyloid in the etiology of Alzheimer\u2019s disease: precursor-product relationships in the derangement of neuronal function. Brain Pathol. 1991;1:241\u201351.","journal-title":"Brain Pathol"},{"key":"740_CR30","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe DJ. The molecular pathology of Alzheimer\u2019s disease. Neuron. 1991;6:487\u201398.","journal-title":"Neuron"},{"key":"740_CR31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256:184\u20135.","journal-title":"Science"},{"issue":"1","key":"740_CR32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9(1):119\u201328.","journal-title":"Lancet Neurol."},{"issue":"9","key":"740_CR33","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrn3983","volume":"16","author":"FK Wiseman","year":"2015","unstructured":"Wiseman FK, Al-Janabi T, Hardy J, et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. 2015;16(9):564\u201374.","journal-title":"Nat Rev Neurosci"},{"key":"740_CR34","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/gps.1545","volume":"21","author":"SL Ball","year":"2006","unstructured":"Ball SL, Holland AJ, Hon J, et al. Personality and behaviour changes mark the early stages of Alzheimer\u2019s disease in adults with Down\u2019s syndrome: findings from a prospective population-based study. Int J Geriatr Psychiatry. 2006;21:661\u201373.","journal-title":"Int J Geriatr Psychiatry."},{"key":"740_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1348\/014466507X230967","volume":"47","author":"SL Ball","year":"2008","unstructured":"Ball SL, Holland AJ, Treppner P, et al. Executive dysfunction and its association with personality and behaviour changes in the development of Alzheimer\u2019s disease in adults with Down syndrome and mild to moderate learning disabilities. Br J Cli. Psychol. 2008;47:1\u201329.","journal-title":"Br J Cli. Psychol."},{"issue":"2","key":"740_CR36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3233\/JAD-170920","volume":"63","author":"AD Dekker","year":"2018","unstructured":"Dekker AD, Sacco S, Carfi A, et al. The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: comprehensive Assessment of Psychopathology in Down Syndrome. J Alzheimers Dis. 2018;63(2):797\u2013819.","journal-title":"J Alzheimers Dis."},{"issue":"1","key":"740_CR37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11065-017-9341-9","volume":"27","author":"BA Lautarescu","year":"2017","unstructured":"Lautarescu BA, Holland AJ, Zaman SH. The early presentation of dementia in people with Down syndrome: a systematic review of longitudinal studies. Neuropsychol Rev. 2017;27(1):31\u201345.","journal-title":"Neuropsychol Rev"},{"key":"740_CR38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cortex.2015.07.032","volume":"73","author":"AD Dekker","year":"2015","unstructured":"Dekker AD, Strydom A, Coppus AM, et al. Behavioural and psychological symptoms of dementia in Down syndrome: early indicators of clinical Alzheimer\u2019s disease? Cortex. 2015;73:36\u201361.","journal-title":"Cortex."},{"key":"740_CR39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1046\/j.1365-2788.2000.00263.x","volume":"44","author":"AJ Holland","year":"2000","unstructured":"Holland AJ, Hon J, Huppert FA, et al. Incidence and course of dementia in people with Down\u2019s syndrome: findings from a population-based study. J Intellect Disabil Res. 2000;44:138\u201346.","journal-title":"J Intellect Disabil Res"},{"issue":"1","key":"740_CR40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3233\/JAD-2012-111613","volume":"29","author":"IT Lott","year":"2012","unstructured":"Lott IT, Doran E, Nguyen VQ, et al. Down syndrome and dementia: seizures and cognitive decline. J Alzheimers Dis. 2012;29(1):177\u201385.","journal-title":"J Alzheimers Dis."},{"issue":"4","key":"740_CR41","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.braindev.2004.07.008","volume":"27","author":"M Men\u00e9ndez","year":"2005","unstructured":"Men\u00e9ndez M. Down syndrome, Alzheimer\u2019s disease and seizures. Brain Dev. 2005;27(4):246\u201352.","journal-title":"Brain Dev."},{"issue":"7","key":"740_CR42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.seizure.2010.04.008","volume":"19","author":"R De Simone","year":"2010","unstructured":"De Simone R, Puig XS, G\u00e9lisse P, et al. Senile myoclonic epilepsy: delineation of a common condition associated with Alzheimer\u2019s disease in Down syndrome. Seizure. 2010;19(7):383\u20139.","journal-title":"Seizure."},{"issue":"3","key":"740_CR43","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2990.1984.tb00351.x","volume":"10","author":"DM Mann","year":"1984","unstructured":"Mann DM, Yates PO, Marcyniuk B. Alzheimer\u2019s presenile dementia, senile dementia of Alzheimer type and Down\u2019s syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol. 1984;10(3):185\u2013207.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"740_CR44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/nbdi.1996.0003","volume":"3","author":"CA Lemere","year":"1996","unstructured":"Lemere CA, Blusztajn JK, Yamaguchi H, et al. Sequence of deposition of heterogeneous amyloid beta-peptides and APOE in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis. 1996;3:16\u201332.","journal-title":"Neurobiol Dis"},{"key":"740_CR45","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1006\/exnr.1997.6777","volume":"150","author":"JB Leverenz","year":"1998","unstructured":"Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol. 1998;150:296\u2013304.","journal-title":"Exp Neurol"},{"issue":"7","key":"740_CR46","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/dneu.22713","volume":"79","author":"EE Abrahamson","year":"2019","unstructured":"Abrahamson EE, Head E, Lott IT, et al. Neuropathological correlates of amyloid PET imaging in Down syndrome. Dev Neurobiol. 2019;79(7):750\u201366.","journal-title":"Dev Neurobiol."},{"key":"740_CR47","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0002-9440(10)64538-5","volume":"157","author":"AM Cataldo","year":"2000","unstructured":"Cataldo AM, Peterhoff CM, Troncoso JC, et al. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer\u2019s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000;157:277\u201386.","journal-title":"Am J Pathol"},{"issue":"12","key":"740_CR48","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, R\u00fcb U, Orantes M, et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791\u2013800.","journal-title":"Neurology."},{"issue":"1","key":"740_CR49","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40478-018-0559-4","volume":"6","author":"YS Davidson","year":"2018","unstructured":"Davidson YS, Robinson A, Prasher VP, et al. The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer\u2019s disease in individuals with Down syndrome. Acta Neuropathol Commun. 2018;6(1):56.","journal-title":"Acta Neuropathol Commun."},{"key":"740_CR50","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nm0796-783","volume":"2","author":"AD Alonso","year":"1996","unstructured":"Alonso AD, Grundke-Iqbal I, Iqbal K. Alzheimer\u2019s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med. 1996;2:783\u20137.","journal-title":"Nat Med"},{"issue":"12","key":"740_CR51","doi-asserted-by":"crossref","first-page":"6923","DOI":"10.1073\/pnas.121119298","volume":"98","author":"AC Alonso","year":"2001","unstructured":"Alonso AC, Zaidi T, Novak M, et al. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments\/straight filaments. Proc Natl Acad Sci USA. 2001;98(12):6923\u201369238.","journal-title":"Proc Natl Acad Sci USA"},{"key":"740_CR52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1742-2094-10-84","volume":"10","author":"DM Wilcock","year":"2013","unstructured":"Wilcock DM, Griffin WS. Down\u2019s syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J Neuroinflammation. 2013;10:84.","journal-title":"J Neuroinflammation."},{"key":"740_CR53","doi-asserted-by":"crossref","first-page":"170276","DOI":"10.1155\/2012\/170276","volume":"2012","author":"DM Wilcock","year":"2012","unstructured":"Wilcock DM. Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer\u2019s disease. Curr Gerontol Geriatr Res. 2012;2012:170276.","journal-title":"Curr Gerontol Geriatr Res."},{"issue":"9","key":"740_CR54","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.neurobiolaging.2015.05.016","volume":"36","author":"DM Wilcock","year":"2015","unstructured":"Wilcock DM, Hurban J, Helman AM, et al. Down syndrome individuals with Alzheimer\u2019s disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer\u2019s disease. Neurobiol Aging. 2015;36(9):2468\u201374.","journal-title":"Neurobiol Aging"},{"issue":"7","key":"740_CR55","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archneurol.2011.36","volume":"68","author":"J Landt","year":"2011","unstructured":"Landt J, D\u2019Abrera JC, Holland AJ, et al. Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar \u03b2-amyloid in adults with down syndrome: safety, acceptability, and feasibility. Arch Neurol. 2011;68(7):890\u20136.","journal-title":"Arch Neurol"},{"issue":"6","key":"740_CR56","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jalz.2011.09.229","volume":"8","author":"BL Handen","year":"2012","unstructured":"Handen BL, Cohen AD, Channamalappa U, et al. Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimers Dement. 2012;8(6):496\u2013501.","journal-title":"Alzheimers Dement."},{"key":"740_CR57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fnbeh.2015.00239","volume":"9","author":"MS Rafii","year":"2015","unstructured":"Rafii MS, Wishnek H, Brewer JB, et al. The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer\u2019s disease biomarkers in down syndrome. Front Behav Neurosci. 2015;9:239.","journal-title":"Front Behav Neurosci."},{"issue":"5","key":"740_CR58","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/WNL.0000000000001212","volume":"84","author":"D Jennings","year":"2015","unstructured":"Jennings D, Seibyl J, Sabbagh M, et al. Age dependence of brain \u03b2-amyloid deposition in Down syndrome: an [18F] florbetaben PET study. Neurology. 2015;84(5):500\u20137.","journal-title":"Neurology."},{"issue":"5","key":"740_CR59","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jalz.2015.07.490","volume":"12","author":"T Annus","year":"2016","unstructured":"Annus T, Wilson LR, Hong YT, et al. The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimers Dement. 2016;12(5):538\u201345.","journal-title":"Alzheimers Dement."},{"key":"740_CR60","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neurobiolaging.2017.04.006","volume":"56","author":"JH Cole","year":"2017","unstructured":"Cole JH, Annus T, Wilson LR, et al. Brain-predicted age in Down syndrome is associated with beta amyloid deposition and cognitive decline. Neurobiol Aging. 2017;56:41\u20139.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"740_CR61","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jalz.2015.05.013","volume":"12","author":"PJ Lao","year":"2016","unstructured":"Lao PJ, Betthauser TJ, Hillmer AT, et al. The effects of normal aging on amyloid-\u03b2 deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B. Alzheimers Dement. 2016;12(4):380\u201390.","journal-title":"Alzheimers Dement."},{"key":"740_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dadm.2017.05.001","volume":"9","author":"PJ Lao","year":"2017","unstructured":"Lao PJ, Handen BL, Betthauser TJ, et al. Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. Alzheimers Dement (Amst). 2017;9:1\u20139.","journal-title":"Alzheimers Dement (Amst)."},{"issue":"23","key":"740_CR63","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.1523\/JNEUROSCI.0730-07.2007","volume":"27","author":"WE Klunk","year":"2007","unstructured":"Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. Version 2. J Neurosci. 2007;27(23):6174\u201384.","journal-title":"J Neurosci."},{"issue":"12","key":"740_CR64","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archneurol.2009.285","volume":"66","author":"VL Villemagne","year":"2009","unstructured":"Villemagne VL, Ataka S, Mizuno T, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009;66(12):1537\u201344.","journal-title":"Arch Neurol"},{"issue":"6","key":"740_CR65","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jalz.2018.01.002","volume":"14","author":"AD Cohen","year":"2018","unstructured":"Cohen AD, McDade E, Christian B, et al. Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer\u2019s disease from late-onset amyloid deposition. Alzheimers Dement. 2018;14(6):743\u201350.","journal-title":"Alzheimers Dement."},{"issue":"3","key":"740_CR66","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392.","journal-title":"Alzheimers Dement."},{"issue":"5","key":"740_CR67","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Sch\u00f6ll","year":"2016","unstructured":"Sch\u00f6ll M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971\u201382.","journal-title":"Neuron"},{"key":"740_CR68","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","volume":"4","author":"VJ Lowe","year":"2016","unstructured":"Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016;4:58.","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"740_CR69","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JAD-170390","volume":"60","author":"MS Rafii","year":"2017","unstructured":"Rafii MS, Lukic AS, Andrews RD, et al. PET imaging of tau pathology and relationship to amyloid, longitudinal mri, and cognitive change in down syndrome: results from the down syndrome biomarker initiative (DSBI). J Alzheimers Dis. 2017;60(2):439\u201350.","journal-title":"J Alzheimers Dis."},{"key":"740_CR70","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/S0002-9440(10)61154-6","volume":"160","author":"MS Forman","year":"2002","unstructured":"Forman MS, Zhukareva V, Bergeron C, et al. Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am J Pathol. 2002;160:2045\u201353.","journal-title":"Am J Pathol"},{"issue":"3","key":"740_CR71","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.neuroimage.2007.09.064","volume":"39","author":"RJ Haier","year":"2008","unstructured":"Haier RJ, Head K, Head E, et al. Neuroimaging of individuals with Down\u2019s syndrome at-risk for dementia: evidence for possible compensatory events. Neuroimage. 2008;39(3):1324\u201332.","journal-title":"Neuroimage."},{"issue":"2","key":"740_CR72","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.trci.2016.02.004","volume":"2","author":"DC Matthews","year":"2016","unstructured":"Matthews DC, Lukic AS, Andrews RD, et al. Dissociation of Down syndrome and Alzheimer\u2019s disease effects with imaging. Alzheimers Dement (N Y). 2016;2(2):69\u201381.","journal-title":"Alzheimers Dement (N Y)."},{"issue":"2","key":"740_CR73","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1212\/WNL.47.2.454","volume":"47","author":"CC Meltzer","year":"1996","unstructured":"Meltzer CC, Zubieta JK, Brandt J, et al. Regional hypometabolism in Alzheimer\u2019s disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology. 1996;47(2):454\u201361.","journal-title":"Neurology."},{"issue":"4","key":"740_CR74","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/archneur.1995.00540280065020","volume":"52","author":"PR Hof","year":"1995","unstructured":"Hof PR, Bouras C, Perl DP, et al. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down\u2019s syndrome. Quantitative regional analysis and comparison with Alzheimer\u2019s disease. Arch Neurol. 1995;52(4):379\u201391.","journal-title":"Arch Neurol."},{"issue":"Pt 4","key":"740_CR75","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/brain\/awh101","volume":"127","author":"SJ Teipel","year":"2004","unstructured":"Teipel SJ, Alexander GE, Schapiro MB, et al. Age-related cortical grey matter reductions in non-demented Down\u2019s syndrome adults determined by MRI with voxel-based morphometry. Brain. 2004;127(Pt 4):811\u201324.","journal-title":"Brain"},{"issue":"1","key":"740_CR76","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1866-1955-5-19","volume":"5","author":"D Mullins","year":"2013","unstructured":"Mullins D, Daly E, Simmons A, et al. Dementia in Down\u2019s syndrome: an MRI comparison with Alzheimer\u2019s disease in the general population. J Neurodev Disord. 2013;5(1):19.","journal-title":"J Neurodev Disord."},{"issue":"1","key":"740_CR77","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1176\/appi.ajp.159.1.74","volume":"159","author":"JS Krasuski","year":"2002","unstructured":"Krasuski JS, Alexander GE, Horwitz B, et al. Relation of medial temporal lobe volumes to age and memory function in nondemented adults with Down\u2019s syndrome: implications for the prodromal phase of Alzheimer\u2019s disease. Am J Psychiatry. 2002;159(1):74\u201381.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"740_CR78","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1017\/S0033291708004054","volume":"39","author":"F Beacher","year":"2009","unstructured":"Beacher F, Daly E, Simmons A, et al. Alzheimer\u2019s disease and Down\u2019s syndrome: an in vivo MRI study. Psychol Med. 2009;39(4):675\u201384.","journal-title":"Psychol Med"},{"issue":"7","key":"740_CR79","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/archneur.64.7.1007","volume":"64","author":"N Schupf","year":"2007","unstructured":"Schupf N, Patel B, Pang D, et al. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol. 2007;64(7):1007\u201313.","journal-title":"Arch Neurol"},{"issue":"18","key":"740_CR80","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.0b013e3181fb448b","volume":"75","author":"N Schupf","year":"2010","unstructured":"Schupf N, Zigman WB, Tang MX, et al. Change in plasma A\u00df peptides and onset of dementia in adults with Down syndrome. Neurology. 2010;75(18):1639\u201344.","journal-title":"Neurology."},{"key":"740_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dadm.2017.02.006","volume":"8","author":"AD Dekker","year":"2017","unstructured":"Dekker AD, Fortea J, Blesa R, et al. Cerebrospinal fluid biomarkers for Alzheimer\u2019s disease in Down syndrome. Alzheimers Dement (Amst). 2017;8:1\u201310.","journal-title":"Alzheimers Dement (Amst)."},{"issue":"10","key":"740_CR82","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1474-4422(18)30285-0","volume":"17","author":"J Fortea","year":"2018","unstructured":"Fortea J, Carmona-Iragui M, Benejam B, et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 2018;17(10):860\u20139.","journal-title":"Lancet Neurol."},{"issue":"1","key":"740_CR83","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-018-0367-x","volume":"10","author":"A Strydom","year":"2018","unstructured":"Strydom A, Heslegrave A, Startin CM, et al. Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. Alzheimers Res Ther. 2018;10(1):39.","journal-title":"Alzheimers Res Ther."},{"issue":"1","key":"740_CR84","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3233\/JAD-190322","volume":"70","author":"MS Rafii","year":"2019","unstructured":"Rafii MS, Donohue MC, Matthews DC, et al. plasma neurofilament light and Alzheimer\u2019s disease biomarkers in down syndrome: results from the down syndrome biomarker initiative (DSBI). J Alzheimers Dis. 2019;70(1):131\u20138.","journal-title":"J Alzheimers Dis."},{"issue":"1","key":"740_CR85","first-page":"e12028","volume":"12","author":"M Mapstone","year":"2020","unstructured":"Mapstone M, Gross TJ, Macciardi F, et al. Metabolic correlates of prevalent mild cognitive impairment and Alzheimer\u2019s disease in adults with Down syndrome. Alzheimers Dement (Amst). 2020;12(1):e12028.","journal-title":"Alzheimers Dement (Amst)."},{"issue":"2","key":"740_CR86","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1352\/1944-7558-125.2.97","volume":"125","author":"BL Handen","year":"2020","unstructured":"Handen BL. The search for biomarkers of Alzheimer\u2019s disease in down syndrome. Am J Intellect Dev Disabil. 2020;125(2):97\u20139.","journal-title":"Am J Intellect Dev Disabil."},{"issue":"3","key":"740_CR87","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1352\/1944-7558-122.3.247","volume":"122","author":"AJ Esbensen","year":"2017","unstructured":"Esbensen AJ, Hooper SR, Fidler D, Outcome Measures Working Group, et al. Outcome Measures for Clinical Trials in Down Syndrome. Am J Intellect Dev Disabil. 2017;122(3):247\u201381.","journal-title":"Am J Intellect Dev Disabil."},{"key":"740_CR88","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/scitranslmed.3002609","volume":"3","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3:111\u201333.","journal-title":"Sci Transl Med."},{"issue":"2","key":"740_CR89","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40263-018-0598-1","volume":"33","author":"MS Rafii","year":"2019","unstructured":"Rafii MS, Aisen PS. Alzheimer\u2019s disease clinical trials: moving toward successful prevention. CNS Drugs. 2019;33(2):99\u2013106.","journal-title":"CNS Drugs"},{"key":"740_CR90","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.trci.2018.10.006","volume":"4","author":"A Strydom","year":"2018","unstructured":"Strydom A, Coppus A, Blesa R, et al. Alzheimer\u2019s disease in Down syndrome: an overlooked population for prevention trials. Alzheimers Dement (N Y). 2018;4:703\u201313.","journal-title":"Alzheimers Dement (N Y)."},{"issue":"8","key":"740_CR91","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.mayocp.2013.04.024","volume":"88","author":"JA Moran","year":"2013","unstructured":"Moran JA, Rafii MS, Keller SM, et al. The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual disabilities. Mayo Clin Proc. 2013;88(8):831\u201340.","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"740_CR92","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/jir.12200","volume":"59","author":"DM Walsh","year":"2015","unstructured":"Walsh DM, Doran E, Silverman W, et al. Rapid assessment of cognitive function in down syndrome across intellectual level and dementia status. J Intellect Disabil Res. 2015;59(11):1071\u20139.","journal-title":"J Intellect Disabil Res"},{"issue":"8","key":"740_CR93","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/gps.4228","volume":"30","author":"R Sheehan","year":"2015","unstructured":"Sheehan R, Sinai A, Bass N, et al. Dementia diagnostic criteria in Down syndrome. Int J Geriatr Psychiatry. 2015;30(8):857\u201363.","journal-title":"Int J Geriatr Psychiatry."},{"key":"740_CR94","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00109-007-0156-7","volume":"85","author":"D Fenili","year":"2007","unstructured":"Fenili D, Brown M, Rappaport R, et al. Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J Mol Med (Berl). 2007;85:603\u201311.","journal-title":"J Mol Med (Berl)"},{"key":"740_CR95","doi-asserted-by":"crossref","first-page":"18495","DOI":"10.1074\/jbc.M906994199","volume":"275","author":"J McLaurin","year":"2000","unstructured":"McLaurin J, Golomb R, Jurewicz A, et al. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J Biol Chem. 2000;275:18495\u2013502.","journal-title":"J Biol Chem"},{"key":"740_CR96","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ana.21051","volume":"60","author":"M Townsend","year":"2006","unstructured":"Townsend M, Cleary JP, Mehta T, et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol. 2006;60:668\u201376.","journal-title":"Ann Neurol"},{"key":"740_CR97","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","volume":"77","author":"S Salloway","year":"2011","unstructured":"Salloway S, Sperling R, Keren R, et al. ELND005-AD201 Investigators A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011;77:1253\u201362.","journal-title":"Neurology."},{"issue":"2","key":"740_CR98","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3233\/JAD-160965","volume":"58","author":"MS Rafii","year":"2017","unstructured":"Rafii MS, Skotko BG, McDonough ME, et al. A randomized, double-blind, placebo-controlled, phase II study of oral ELND005 (scyllo-Inositol) in young adults with down syndrome without dementia. J Alzheimers Dis. 2017;58(2):401\u201311.","journal-title":"J Alzheimers Dis."},{"issue":"23","key":"740_CR99","doi-asserted-by":"crossref","first-page":"9810","DOI":"10.1073\/pnas.0703137104","volume":"104","author":"A Muhs","year":"2007","unstructured":"Muhs A, Hickman DT, Pihlgren M, et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci USA. 2007;104(23):9810\u20135.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"1","key":"740_CR100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46\u201354.","journal-title":"Neurology."},{"issue":"3","key":"740_CR101","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41582-018-0132-6","volume":"15","author":"IT Lott","year":"2019","unstructured":"Lott IT, Head E. Dementia in down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol. 2019;15(3):135\u201347.","journal-title":"Nat Rev Neurol."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00740-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-020-00740-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00740-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T23:37:31Z","timestamp":1622936251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-020-00740-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,6]]},"references-count":101,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["740"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00740-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,6]]},"assertion":[{"value":"6 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding sources were used to assist with the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Michael S. Rafii has served as consultant to AC Immune.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}